A recent study shows that over-the-counter aspirin can mitigate the severe impact of COVID-19, including hospitalization, ventilation, and death.
The Jerusalem Post reports that low-dose aspirin can reduce the need for ventilation by 44% and projects lowering ICU admissions by 43% and in-hospital mortality by 47%. A George Washington University study corroborates the findings.
Dr. Jonathan Chow spoke recently of the study and the relationship between COVID-19 and blood clots. “As we have learned about the connection between blood clots and COVID-19, we knew that aspirin—used to prevent stroke and heart attack—could be important for COVID-19 patients. Our research found an association between low-dose aspirin and decreased severity of COVID-19 and death.”
A report published in the Lancet Open Access eClinical Medicine included this statement from lead author Sameh Hozayen: “Blood thinners are medications prescribed to prevent blood clots in patients with a prior blood clot in their lungs or legs.
They also prevent blood clots in the brain secondary to abnormal heart rhythms, like atrial fibrillation. Blood thinners are the standard of treatment in these diseases, which is why we looked at data to see if it impacted hospitalizations related to COVID-19.”
The study found that blood thinners, started before or after the onset of a COVID-19 infection, reduced death by nearly half.
The benefit of a regiment of common aspirin is not new, but has been affirmed recently in high-profile studies. This month, Medical Express reported on the positive impact aspirin can have on COVID-19 patients, citing studies from the Universities of Minnesota and Basel University in Switzerland.
These recent studies that recommend a modest aspirin regiment come at a time when many are looking for ways to address reports of increased blood-clotting among the vaccinated. Experts note that aspirin, properly dosed, can decrease the risk of stroke and myocardial infarction.
Scroll down to leave a comment and share your thoughts.
